Ali Zarrin, PhD

Dr. Ali Zarrin is the Chief Scientific Officer at TRexBio, where he leads the company’s scientific strategy and oversees all aspects of drug discovery, from target identification and validation through preclinical development and early clinical translation. He brings 18 years of drug discovery experience in translational immunology, spanning the discovery of novel targets through the advancement of therapeutic candidates into the clinic.

Before joining TRexBio, Dr. Zarrin held key leadership roles in Early Research and Development at Genentech, where he was instrumental in advancing multiple therapeutic programs across cancer, inflammatory, and autoimmune indications. His work encompassed diverse mechanistic pathways and included leading disease area research strategies with a particular focus on autoimmune and inflammatory diseases.

Dr. Zarrin is an inventor on 6 patents and has authored more than 47 scientific publications, including 20 primary research articles, in leading journals such as Nature, Nature Immunology, Nature Reviews Drug Discovery, Nature Reviews Immunology, Science, Science Signaling, and PNAS.

He earned his BS from the University of Minnesota and his PhD in Immunology from the University of Toronto. He then pursued postdoctoral studies in the laboratory of pioneering geneticist and molecular immunologist Fred Alt at HHMI/Harvard.